Page 2 - Ac Immune News Today : Breaking News, Live Updates & Top Stories | Vimarsana

AC Immune Announces Pricing of Underwritten Offering of Common Shares Lausanne, Switzerland, December 15, 2023 – AC Immune SA (Nasdaq: ACIU) (the “Company” or “AC Immune”), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it has priced an underwritten offering of 14.3 million of its common shares at a price of USD 3.50 per share. The Company expects the gross proceeds from the offering, before deducting the underwriting

AC Immune SA (NASDAQ:ACIU – Get Free Report) fell 6.2% during trading on Tuesday . The stock traded as low as $3.50 and last traded at $3.62. 99,878 shares were traded during mid-day trading, a decline of 70% from the average session volume of 336,394 shares. The stock had previously closed at $3.86. Analyst Ratings […]

By Colin Kellaher AC Immune has named Christopher Roberts chief financial officer, removing the interim tag he has carried since early 2022. The Lausanne,...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023 Lausanne, Switzerland, October 5, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company Management will present a corporate overview and participate in one-on-one investor meetings during the Jefferies 2023 CNS & Neuro Summit, taking place in-person in New York City on October 11-12, 2023. AC Immune’s cor